Summary
Apolipoproteins, such as apolipoprotein A-I (apoA-I), can stimulate cholesterol efflux from cells expressing the ABC transporter, ABCA1. The nature of the molecular interaction between these cholesterol acceptors and ABCA1 is controversial, and models suggesting a direct protein-protein interaction or indirect association have been proposed.
To explore this issue, we performed competition binding and chemical cross-linking assays using six amphipathic plasma proteins and an 18 amino acid amphipathic helical peptide. All seven proteins stimulated lipid efflux and competed the cross-linking of apoA-I to ABCA1. Cross-linking of apoA-I to ABCA1 was saturable and occurred at high affinity (Kd of 7.0±1.9 nM), as was cross-linking of apoA-II. Following binding to ABCA1, apoA-I rapidly dissociated (t 1/2 25min) from the complex and was released back into the media. A mutant form of ABCA1 (W590S) that avidly binds A-I, but fails to promote cholesterol efflux, released apoA-I with similar kinetics but without transfer of cholesterol to apoA-I. Thus, a high affinity, saturable, protein-protein interaction occurs between ABCA1 and all of its amphipathic protein ligands. Dissociation of the complex leads to the cellular release of cholesterol and the apolipoprotein. However, dissociation is not dependent on cholesterol transfer, which is a clearly separable event, distinguishable by ABCA1 mutants.
correlates with its ability to act as an efflux acceptor (7) . Evidence for ABCA1's role in altering the lipid environment of the plasma membrane comes from observations of enhanced phosphotidylserine expression on ABCA1-expressing cells, as well as an increased susceptibility of membrane cholesterol to oxidation by cholesterol oxidase (2, 8) .
In contrast to the action at a distance model, the direct association model proposes that ABCA1 acts as a receptor to which the apoA-I ligand directly binds. This direct interaction is proposed to stimulate ABCA1's cholesterol efflux activity, resulting in the transfer of cholesterol and phospholipids onto the acceptor apolipoprotein. Evidence for the direct association model comes from chemical cross-linking studies, performed in our laboratory and others, that indicate that apoA-I and ABCA1 are in very close proximity (< 7 angstroms) (3) (4) (5) . Using mutant forms of ABCA1, we have identified a transporter that cross-links to ABCA1 but does not promote lipid efflux (5), a finding now confirmed by several laboratories (9, 10) . However, we have been unable to find a mutant that effluxes cholesterol without being able to cross-link. These data suggest that a binding interaction between apoA-I and ABCA1 is necessary for cholesterol efflux to proceed. If so, the lack of primary amino acid sequence similarity between the many acceptor apolipoproteins that stimulate ABCA1-mediated cholesterol efflux raises questions about the mechanism by which these disparate ligands could functionally activate the same transporter (11) .
In this report, we performed more detailed studies of the nature of the molecular interaction between ABCA1 and amphipathic apoliprotein acceptors. Using competition binding assays coupled to cross-linking, we provide evidence that all of the amphipathic helical apolipoproteins can compete for a shared interaction with ABCA1. Using both radiolabeled apo A-I and A-II, we show that these interactions are direct, high affinity, and saturable. We also determined that the ABCA1/apoA-I complex has a half-life of less than 30 mins and that the dissociation of this complex is not dependent on the transfer of cholesterol to the acceptor, as had been previously proposed. These data indicate that ABCA1 and its apolipoprotein acceptors form a high affinity receptor-ligand complex whose formation is dependent on the presence of the structural motif of an amphipathic helix in the acceptor. The rapid dissociation of the complex is temporally associated with cholesterol transfer in wild type ABCA1 transporters, but an ABCA1 mutant demonstrates that dissociation does not depend on the transfer of lipid.
Experimental Procedures
Materials-The DSP and DSG cross-linkers (Pierce, Rockford, IL) were used as previously described (5) . Cell culture reagents were from Gibco (Rockville, MD).
Apolipoproteins and annexin-V were from Calbiochem (San Diego, CA), Biodesign (Saco ME) and Biovision (Mountain View, CA). Radionucleotides were from NEN (Boston, MA).
Efflux and cross-linking assays-Cholesterol efflux assays were performed in 293 cells transfected with wild type and mutant ABCA1 cDNAs, as we reported (5) . Efflux acceptors were incubated with ABCA1 expressing cells at 10ug/ml and cross-linking assays conducted as described previously (3, 5) . Apo A-I and A-II were radio-labeled with 125 I to a specific activity of ~ 1000 and 1300 cpm/ng, respectively, using Iodo-Beads (Pierce) according to the manufacturer's instructions. Unincorporated radionucleotides were eliminated by gel filtration and the efficiency of the separation (>99%) was determined by trichloroacetic acid precipitation. Radio-labeled apo A-I and A-II were added to cells at 1ug/ml and unlabeled competitors were used at a 30-fold molar excess.
The 18A amphipathic helical peptide (DWLKAFYDKVAEKLKEAF) as well as a scramble version (18S, KDVYAFEAKKKLLWEDFA) were synthesized with amino terminal acetyl and carboxy terminal amide blocking groups and were purified to greater than 95% using high pressure liquid chromatography (14) . Affinity constants for complex formation between ABCA1 and apo A-I or A-II were calculated using Prism GraphPad software (San Diego, CA). Phosphor pixels of cross-linked apolipoprotein were converted to ng of apolipoprotein using equations (r 2 =0.98) derived from curves of 
Results:
The exchangeable apolipoproteins that contain amphipathic helices include apo A-I, A-II, C-I, C-II, C-III, and apo E. The roles of apoE and apoA-I in ABCA1-mediated cholesterol efflux have been well documented (7, 12 (11) . Our data confirm these earlier findings and demonstrate that the prior use of the ABCA1-GFP chimera did not result in a promiscuous interaction with multiple apolipoproteins. To test the importance of the amphipathic helical structure in stimulating efflux, we utilized another apolipoprotein, apoH. ApoH associates with HDL, but does so by binding phospholipids through a non-amphipathic mechanism (13) . In contrast to the other exchangeable apolipoproteins, apoH was unable to stimulate ABCA1 efflux activity (Fig. 1A ).
Having established that a variety of exchangeable apolipoproteins could act as stimulators of ABCA1 efflux activity, we sought to determine whether they might share a similar site of interaction with the transporter. To address this issue, a competition binding assay of apoA-I to ABCA1 was used. As it has proven difficult to measure specific binding of 125 I-apoA-I to ABCA1-expressing cells at 4 o C, a cross-linking assay performed at 37 o C was employed, using a thiol-soluble cross-linker, DSP (Fig. 1B) . Apo A-I, A-II and C-I were found to block the cross-linking of 125 I-apoA-I to ABCA1 by greater than 90%. Apo C-II, C-III and E all competed > 70% of the cross-linking. In a separate assay, the competition of unlabeled apoA-I or apoA-II for radiolabeled apoA-I cross-linking was compared to that seen with apoH ( Figure 1B) . Again, apo A-I and A-II reduced 125 I-apoA-I cross-linking to background levels, while apoH reduced cross-linking by only 22% (Fig. 1B) . Annexin-V, which has been reported to bind phospholipids that are translocated to the external leaflet of the plasma membrane by ABCA1 activity, was also tested in this assay (2) . Like apoH, annexin-V caused a very modest (< 7%) inhibition of 125 I-apoA-I cross-linking (Fig. 1B ). Finally, we tested whether a synthetic 18 amino acid amphipathic peptide that has previously been reported to function effectively as an efflux acceptor (14) Although the W590S mutant was found to be associated with substantially more radiolabeled apoA-I at time zero, its dissociation rate from the apoprotein (t 1/2 of 30.1 mins) did not differ markedly from that measured for the wild type transporter (t 1/2 of 24.6 min (Fig. 4B, graph) .
We next determined if the dissociation of the apoA-I/ABCA1 complex was kinetically linked to the transfer of cholesterol to apoA-I. Cells expressing wild type ABCA1 released significantly more radiolabeled apoA-I compared to the mocktransfected cells ( Figure 4C , and data not shown). The release of apoA-I from the cells mirrored the decay of the apoA-I/ABCA1 complex, with the release of apoA-I reaching a plateau by 240 min. 50% of the maximal amount of A-I released occurred within the first 40 min. Cells expressing the W590S mutant also released the apoA-1 back into the media at a similar rate. These results, along with the measurements of the kinetics of dissociation described above, indicate that the cholesterol efflux defect in the W590S
mutant cannot be accounted for by either a failure of the apoA-I/ABCA1 complex to dissociate or an ectopic release of apoA-1. Significantly, the apoA-I released from cells expressing wild type ABCA1 migrated more slowly on native gels than did the apoA-I released from cells expressing the mutant (Fig. 4D) . The apoA-I released from the cells expressing the W590S mutant migrated at the expected molecular weight of lipiddepleted, monomeric apoA-I (Fig. 4D) . These results suggested that the apoA-I released by cells expressing wild type ABCA1 had acquired lipid, whereas the apoA-I released from cells expressing the W590S mutant had not. To confirm this, cells were labeled with 14 C-cholesterol and the experiment repeated using unlabeled apoA-I. As expected, 14 Ccholesterol was found in increased amounts in the pool of apoA-I released by cells expressing the wild type transporter. Cells that were either mock-transfected or expressed the W590S mutant had similarly low levels of 14 C-cholesterol associated with apoA-I in the media (Fig. 4D, graph) . As the W590S mutant had a similar impairment in its ability to transfer phosphatidylcholine to apoA-I (data not shown), the mutant does not provide a tool for dissociating the mechanisms of efflux of these two lipids.
Discussion
In this report, we have investigated the molecular interaction between ABCA1
and a series of exchangeable apolipoproteins that can stimulate cholesterol efflux from cells. Apolipoproteins that contained amphipathic helices were able to block the crosslinking of radiolabeled apoA-I to ABCA1, whereas non-amphipathic lipid binding proteins were not. These effects appear to involve competition for direct binding to ABCA1, as we were able to demonstrate direct cross-linking of another apolipoprotein, amphipathic helix itself appears to be the structural element that allows an apolipoprotein to interact with ABCA1, as an 18 amino acid peptide that has been demonstrated to adopt an amphipathic helical conformation was also able to efficiently compete for the binding of apoA-I to ABCA1 (14) .
Our work indicates that the various efflux acceptors, including a synthetic 18A
peptide, are able to compete for the direction interaction of apoA-I with ABCA1, despite substantial differences in their primary amino acid sequence. Indeed, although the exchangeable apolipoproteins are thought to have evolved from a common ancestor gene they vary greatly in their overall length and only share from 20 to 30% amino acid identity (15) . Despite this divergence the exchangeable apolipoproteins have strongly conserved their amphiphathic helical character. We propose that the binding of an efflux acceptor to ABCA1 relies on this amphipathic helical structure, with its separation of hydrophilic and hydrophobic surfaces on opposite sides of the helix. That an amphipathic helical motif can participate in protein-protein interactions that are not strongly dependent upon primary sequence has a precedent in the interaction between the regulatory subunits of cAMP-dependent protein kinase (PKA) and its anchoring proteins (16) . Like ABCA1, PKA is also able to form high affinity complexes (~K d of 4 nM) with a variety of docking proteins (17) . These interactions are dependent upon the docking protein containing an amphipathic helix. Nuclear magnetic resonance solution structures have provided structural evidence for the plasticity of this interaction by showing that the hydrophobic face of the docking protein amphipathic helix is bound by a hydrophobic groove on the regulatory subunit of PKA (18) . On the regulatory subunit of PKA the groove is formed by a X-type four helix bundle that presents a hydrophobic patch with which the hydrophobic face of the amphipathic helix interacts. Whether ABCA1 is able to bind amphipathic helices through a similar hydrophobic patch remains to be determined. Clearly, additional studies identifying the residues on ABCA1 involved in the cross-linking reactions will be helpful in characterizing the mechanism by which ABCA1 directly interacts with the various efflux acceptors.
To characterize how complex formation relates to the release of apoA-I and cholesterol efflux, we developed an off-rate protocol that measures the dissociation of the apoA-I/ABCA1 complex. For wild type ABCA1, we found that the complex dissociated with a half-life of 25 min. As the amount of apoA-I released reached a half maximum, by 40 min, these kinetics are consistent with the hypothesis that the released, lipid enriched apoA-I derives exclusively from the dissociation of the transporter/apoprotein complex.
By 4 hours, no further release of apoA-I was detectable, consistent with the reduction of the apoA-I/ABCA1 complex by more than 95%. For cells expressing wild type ABCA1, the released apoA-I contained cholesterol, though lipid transfer was not necessary for release (see below). We also found that cell association measurements for apoA-I binding had a nearly 20-fold lower affinity (137 nM vs 7 nM, respectively) than that measured for the specific cross-linking of apoA-I to ABCA1. This measurement is in good accord with a recent report by Gillotte-Talyor, et. al. that showed the rate constant for cholesterol efflux to be 25 nM, as compared to a Kd for apoA-I cellular binding of 700 nM (19) . In contrast, Remaley et. al reported a higher affinity binding site (22 nM) for apoA-I in cells expressing ABCA1 than either we or Gillote-Taylor et al could measure using standard radiolabeled binding assays (11) . At present, the relationship between such high affinity binding sites and the cross-linking complex we describe in this report is unclear, as we
have been unable to demonstrate formation of the cross-linking complex when the initial apoA-I cell binding assay is carried out at 4 0 C.
In our studies we compared the dissociation behavior of wild type ABCA1/apoA-I complexes to those formed with the W590S ABCA1 mutant. The latter is fully competent to form a complex with apoA-I but it fails to efflux cholesterol normally. The W590S mutant, like wild type ABCA1, was not able to form a cross-linkable complex with apoA-I at 4 0 C. At 37 0 C, apoA-I dissociated from the W590S mutant at a rate similar to that measured using the wild type ABCA1 (t 1/2 30 vs. 25 min, respectively). However, only wild type ABCA1 was able to transfer cholesterol to the released apoA-I. These results suggest the W590S mutant binds and releases apoA-I in a normal manner, but that these processes are uncoupled from the transfer of cholesterol to the released apoA-I. Our results indicate the W590S mutant has a similar impairment in the transfer of phospholipid, and as reported by Rigot et. al, the mutant does not stimulate the translocation of phosphatidylserine to the outer leaflet of the plasma membrane (9).
These results are of significance, as it has been speculated that the release of apoA-I from ABCA1 might be a consequence of the transfer of lipid to the apolipoprotein by ABCA1, with a consequent reduction in binding affinity (1). If this mechanism were operative, it seems unlikely that the apoA-I would dissociate from the W590S mutant with the kinetics we have measured. The behavior of the W590S mutant/apoA-I complex indicates that cellular release of apoA-1 and transfer of cholesterol and phospholipid are separable events, and thus are likely distinct steps in the efflux mechanism.
In summary, our results support an efflux model in which ABCA1 can form specific high affinity complexes with a variety of apolipoproteins. The amphipathic helix was found to be the structural motif that determined an apolipoprotein's ability to form a complex with ABCA1. The competition studies suggest that all of the amphipathic apolipoproteins could be directly interacting with common site on the transporter, possibly a hydrophobic patch, but more detailed structural analysis of the ABCA1 binding locus will be needed before that conclusion can be made with certainty. Our results do not appear to be compatible with an indirect model of efflux, where ABCA1 merely flips lipids in the plasma bilayer that are subsequently micro-solublized by apoA-I (2, 7, 20) . A more recently proposed hybrid model, in which apoA-I first interacts with the lipid bilayer and then, though lateral diffusion, subsequently forms a complex with ABCA1, is in better agreement with our data (6) . This model could also explain our inability to measure cross-linking complexes when the apolipoprotein binding assay is done at temperatures below that which permit the apolipoprotein to diffuse in the membrane. Our work has measured the affinity of binding of apoA-I to ABCA1 and determined it to be nanomolar. We have also determined the dissociation kinetics for the apolipoprotein/transporter complex, demonstrating that its half-life is 25-30 minutes.
Following complex formation, the apolipoprotein is released from wild type ABCA1 with its associated lipid. The W590S ABCA1 mutant demonstrates that this release is not dependent on cholesterol transfer to the acceptor apolipoprotein, indicating that release and cholesterol transfer are separable events in the efflux process. These results form the basis for future studies aimed at exploring the molecular mechanism of ABCA1 mediated cholesterol efflux to apolipoprotein acceptors. 
